We’re on a mission to develop novel therapies for SCN2A—join us
Community News
This page is dedicated to keeping you up to date on the latest SCN2A news and studies. Here you will be able to explore the latest articles, contribute to community posts, read other people’s stories, and much more.
May 03, 2021
Your Voice Is Important
At Praxis, we believe that if families and caregivers are a part of the research and development process it will improve our chances to successfully deliver a potentially disease-modifying treatment to patients with mutations in the SCN2A gene.
Read More >May 03, 2021
FDA Grants Praxis ODD for PRAX-562 for the Treatment of SCN2A-DEE
On Wednesday, April 28, Praxis was granted orphan-drug designation (ODD) by the FDA for PRAX-562 for “treatment of SCN2A developmental and epileptic encephalopathy."
Read More >Apr 01, 2021
Thank You SCN2A Community
We would like to extend our sincere gratitude to SCN2A community members who joined us for our virtual community discussions in March. We hope you found the information helpful.
Read More >Mar 23, 2021
Upcoming SCN2A Virtual Event: An introduction to Praxis, exploring potential treatments for the SCN2A community
Like you, we at Praxis Precision Medicines (Praxis) envision a future where there is greater understanding of SCN2A-related gene mutations and better treatments to help the children and families affected by this rare disorder.
Read More >Mar 18, 2021
Praxis and The Florey Institute Collaborate on Innovative SCN2A Research
Exciting news for the SCN2A community! Praxis has recently entered into an innovative research collaboration with The Florey Institute of Neuroscience and Mental Health.
Read More >Feb 24, 2021
Honoring International SCN2A Awareness Day
At Praxis, we honor International #SCN2A Awareness Day and remain committed to providing therapies for patients as efficiently as possible.
Read More >Feb 16, 2021
Praxis Precision Medicines Partners With Ciitizen To Improve Patient-Guided Drug Development
Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE
Read More >Jan 07, 2021
Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations For Severe Pediatric Epilepsy Programs
FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE
Read More >
